The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: Bladder cancer and chronic kidney disease

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Lee, Mei Yueh ^a,b,c   Hsiao, Pi Jung ^b,c   Yang, Yi Hsin ^b   Lin, Kun Der ^b,c   Shin, Shyi Jang ^b,c  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE;

ADULT; AGE; ARTICLE; BLADDER CANCER; CHRONIC KIDNEY DISEASE; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SEX; TAIWANESE; TREATMENT DURATION; URINARY TRACT DISEASE; YOUNG ADULT;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TAIWAN; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84897487863     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085479     Document Type: Article

References (39)

1. Tachibana K, Yamasaki D, Ishimoto K, Doi T (2008) The role of PPARs in cancer. PPAR Res 2008:102737.
2. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435. (Pubitemid 34177889)
3. Varley CL, Southgate J (2008) Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol 60:435-441.
4. Varley CL, Bacon EJ, Holder JC, Southgate J (2009) FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation. Cell Death Differ 16:103-114.
5. Varley CL, Stahlschmidt J, Smith B, Stower M, Southgate J (2004) Activation of peroxisome proliferators-activated receptor-c reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 164:1789-1798. (Pubitemid 38529781)
6. IARC Working Group (1999) Consensus Report. IARC Sci Publ 147:1-32.
7. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, et al (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55:1953-1962.
8. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916-922.
9. Piccinni C, Motola D, Marchesini G, Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369-71.
10. Takayama S, Sieber SM, Adamson RH, Thorgeirsson UP, Dalgard DW, et al (1998) Long-term feeding of sodium saccharin to nonhuman primates: Implications for urinary tract cancer. J Natl Cancer Inst 90:19-25. (Pubitemid 28078076)
11. Cohen SM (1995) Role of urinary physiology and chemistry in bladder carcinogenesis. Food Chem Toxicol 33:715-730.
12. El-Hage J (2005) Peroxisome proliferation-activated receptor agonists: Carcinogenicity findings and regulatory recommendations. International Atherosclerosis Society Symposium on PPAR, Monte Carlo.
13. Cohen SM (1998) Urinary bladder carcinogenesis. Toxicol Pathol 26:121-127.
14. Cohen SM (1999) Calcium phosphate-containing urinary precipitate in rat urinary bladder carcinogenesis. IARC Sci Publ 147:175-189.
15. IARC Working Group (1999) Consensus Report. IARC Sci Publ 147:1-32.
16. Klaunig JD, Babich MA, Baetcke KP, Cook JC, Corton JC, et al (2003) PPARc agonist-induced rodent tumors: Modes of action and human relevance. Crit Rev Toxicol 33:655-780. (Pubitemid 38037444)
17. Varley CL, Stahlschmidt J, Lee W, Holder J, Dibble C, et al (2003) Role of PPARc and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci 117:2029-2036. (Pubitemid 38745136)
18. Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, et al (2007) Kidney function and markers of inflammation in elderly persons without chronic kidney disease: The health, aging, and body composition study. Kidney Int 71:239-244. (Pubitemid 46160924)
19. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Cholesterol and Recurrent Events (CARE) Trial Investigators: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68:237-245. (Pubitemid 43181381)
20. de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, et al (2006) Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J Am Soc Nephrol 17 [Suppl 3]:S206-S212. (Pubitemid 44865250)
21. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867. (Pubitemid 36019639)
22. Jorgensen L, Heuch I, Jenssen T, Jacobsen BK (2008) Association of albuminuria and cancer incidence. J Am Soc Nephrol 19:992-998.
23. Cengiz K (2002) Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 33:121-126.
24. Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, et al (2009) Association of CKD and cancer risk in older people. J Am Soc Nephrol. 6:1341-1350.
25. Grimm RH Jr, Neaton JD, Ludwig W (1985) Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 254:1932-1937. (Pubitemid 15249094)
26. Friedman GD, Fireman BH (1991) The leukocyte count and cancer mortality. Am J Epidemiol 133:376-380.
27. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, et al (2006) Association between circulating white blood cell count and cancer mortality: A population-based cohort study. Arch Intern Med 166:188-194. (Pubitemid 43144942)
28. Krepinsky J, Ingram AJ, Clase CM (2000) Prolonged sulfonylurea- induced hypoglycemia in diabetic patients with endstage renal disease. Am J Kidney Dis 35:500-505.
29. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, et al (2001) Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147-152. (Pubitemid 32449136)
30. Yale JF (2005) Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol. 16 Suppl 1:S7-10.
31. Gan SC, Barr J, Arieff AI, Pearl RG (1992) Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 152:2333-2336.
32. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, et al.(2003) Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43:252-259. (Pubitemid 36232653)
33. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, et al (2003) Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41:1364-1372. (Pubitemid 36438998)
34. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, et al (2001) Heart and Estrogen/progestin Replacement Study (HERS) Investigators: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 38:705-711. (Pubitemid 32835740)
35. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636. (Pubitemid 32322240)
36. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, et al (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182-187.
37. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, et al (2005) Glycemic status and development of kidney disease: The Framingham Heart Study. Diabetes Care 28:2436-2440. (Pubitemid 41384290)
38. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, et al (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404-1412. (Pubitemid 41716524)
39. Davies DF, Shock NW (1950) Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 29:496-507.